Doris-Ann was quoted in MedTech Insight in an article which examined genomic testing access in the UK. The publication concluded that there was still much work to be done within the NHS to fully take advantage of genomic testing – pointing squarely at an ABPI report which suggests several recommendations. They also suggested that the UK can learn much from its European counterparts.
Doris-Ann noted complications in funding pathways and market access which hampered IVD companies. She said, “BIVDA is working with Charles River Associates to develop a novel, evidence-based assessment of the value and implementation of genomic testing in the UK.”
“Preliminary insights from our research have highlighted that many companies with advanced in vitro diagnostic tools or related services often lack clarity over the regulatory, value assessment and reimbursement pathways in the UK… more work is potentially required to establish more systematic opportunities for collaboration, driving increased access to such innovative technologies to amplify the benefits for all – most importantly, patients.”
The full article can be accessed here.